Patents Examined by Joseph K. McKane
  • 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity
    Patent number: 8288556
    Abstract: Compounds of Formulas 1 and 2 where the variables have the meaning disclosed in the specification, have analgesic and in some cases immunostimulant activity.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: October 16, 2012
    Assignees: Allergan, Inc., Exonhit Therapeutics SA
    Inventors: Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello
  • Diaminothiazoles useful as Axl inhibitors
    Patent number: 8288382
    Abstract: Diaminothiazoles and pharmaceutical compositions containing them are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the diaminothiazoles in treating diseases or conditions associated with Axl activity are also disclosed.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: October 16, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Jing Zhang, Raj Singh, Sacha Holland
  • Napthalimide-benzimidazole hybrids as potential antitumor agents and process for the preparation thereof
    Patent number: 8288387
    Abstract: The present invention provides the compounds of general formula 5 and 9 useful as potential antitumour agents against human cancer cell lines. The present invention further provides the process for preparation of napthalimide-benzimidazole hybrids of general formula 5 and 9, n-1-2, R=n-methylpiperazine or morpholine (Formula 9), wherein: n=2-3, m=2-3 and R=n-methylpiperazine or morpholine.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: October 16, 2012
    Assignee: Council of Scientific & Industrial Research
    Inventors: Kamal Ahmed, Praveen Kumar Pogula
  • Imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use
    Patent number: 8283370
    Abstract: Embodiments disclosed herein relate to new imidazolidinedione derivatives, methods of making these compounds, and methods of using the same to prevent, treat, or inhibit malaria in a subject.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: October 9, 2012
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Ai Jeng Lin, Michael P. Kozar, Michael T. O'Neil, Alan J. Magill, David L. Saunders
  • Processes for the preparation and purification of gabapentin enacarbil
    Patent number: 8283487
    Abstract: Gabapentin enacarbil was prepared and purified from intermediates such as 1-haloalkyl carbamate or carbonate and diacid acetal skeleton. For example, a 1-haloalkyl carbonate or carbamate was prepared by combining a C1 to C10 alcohol or C1 to C10 primary amine, a solvent selected from the group consisting of: acetonitrile, C3 to C7 ketone, C5 to C10 ether, C2 to C7 ester, C5 to C10 hydrocarbon and a combination thereof; a 1-haloalkyl haloformate of the following formula: wherein each X is independently selected from Br, I, or Cl; R1 is alkyl or H; and a C6 to C21 tertiary amine.
    Type: Grant
    Filed: November 26, 2009
    Date of Patent: October 9, 2012
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Elena Ben Moha-Lerman, Tamar Nidam, Meital Cohen, Sharon Avhar-Maydan, Anna Balanov
  • 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
    Patent number: 8283348
    Abstract: The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: October 9, 2012
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
    Inventors: Angelo Guglielmotti, Guido Furlotti, Giorgina Mangano, Nicola Cazzolla, Barbara Garofalo
  • Thiourethane compound and photosensitive resin composition
    Patent number: 8283095
    Abstract: It is an object of the present invention to provide a photopolymerization initiator composition having high sensitivity and excellent storage properties, a photosensitive composition containing the photopolymerization initiator composition, and a thiourethane compound preferable for the photopolymerization initiator composition. The thiourethane compound of the present invention has 2 to 6 units each of which contains a moiety represented by the following formula (i) and a moiety represented by the following formula (ii). wherein R1 is a hydrogen atom or a methyl group, and R2 is —CO—, —COO— or —COOR3— (wherein R3 is an alkylene group of 2 to 6 carbon atoms).
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: October 9, 2012
    Assignee: Showa Denko K.K.
    Inventors: Haruhiko Ikeda, Hideo Miyata, Yotaro Hattori, Katsumi Murofushi
  • Monocyclic Heteroaryl compounds
    Patent number: 8278307
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: October 2, 2012
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: William C. Shakespeare, Wei-Sheng Huang, David C. Dalgarno, Xiaotian Zhu, R. Mathew Thomas, Yihan Wang, Jiwei Qi, Rajeswari Sundaramoorthi, Dong Zou, Chester A. Metcalf, III, Tomi K. Sawyer, Jan Antoinette C. Romero
  • Heterocyclic inhibitors of necroptosis
    Patent number: 8278344
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: October 2, 2012
    Assignees: The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College, Tufts University
    Inventors: Gregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterev
  • Therapeutic compounds
    Patent number: 8278347
    Abstract: A compound having a structure is disclosed herein. Compositions, medicaments, and therapeutic methods related thereto are also disclosed.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: October 2, 2012
    Assignee: Allergan, Inc.
    Inventors: Yariv Donde, Jeremiah H. Nguyen
  • Process for the preparation of an alkylene carbonate and an alkylene glycol
    Patent number: 8273912
    Abstract: The invention provides a reaction system for the production of an alkylene carbonate comprising: an epoxidation zone containing an epoxidation catalyst located within an epoxidation reactor; a carboxylation zone containing an bromide-containing carboxylation catalyst located within an alkylene oxide absorber; and one or more purification zones containing a purification absorbent capable of reducing the quantity of bromide-containing impurities in a feed comprising a recycle gas, which purification zones are located upstream from the epoxidation zone; and a process for the production of an alkylene carbonate and an alkylene glycol.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: September 25, 2012
    Assignee: Shell Oil Company
    Inventors: Wayne Errol Evans, Martin Lysle Hess, Marek Matusz, Eugene Marie Godfried Andre Van Kruchten
  • Phenoxy acetic acid derivatives
    Patent number: 8273769
    Abstract: The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: September 25, 2012
    Assignee: Merck Serono SA
    Inventors: Stefano Crosignani, Catherine Jorand-Lebrun, Christophe Cleva, Adeline Pretre
  • P2X7R antagonists and their use
    Patent number: 8268861
    Abstract: The present application is directed to novel P2X7R antagonists that are N-indol-3-yl-acetamide and N-azaindol-3-yl-acetamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: September 18, 2012
    Assignee: Affectis Pharmaceuticals AG
    Inventor: Michael C Boes
  • Selective androgen receptor modulators
    Patent number: 8268872
    Abstract: This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig and intermediates useful in the preparation of same.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: September 18, 2012
    Assignee: Radius Health, Inc.
    Inventor: Chris P. Miller
  • Processes for preparing amines and catalysts for use therein
    Patent number: 8268995
    Abstract: Processes for preparing an amine, which processes comprise: reacting a reactant selected from the group consisting of primary alcohols, secondary alcohols, aldehydes, ketones, and mixtures thereof, with hydrogen and a nitrogen compound selected from the group consisting of ammonia, primary amines, secondary amines and mixtures thereof, in the presence of a zirconium dioxide-, copper- and nickel-containing catalyst; wherein the catalyst comprises a catalytically active composition which comprises, before reduction with hydrogen, oxygen compounds of zirconium, copper, and nickel, and 0.2 to 40% by weight of an oxygen compound of cobalt, calculated as CoO, 0.1 to 5% by weight of an oxygen compound of iron, calculated as Fe2O3, and 0.1 to 5% by weight of at least one oxygen compound of lead, tin, bismuth or antimony, calculated as PbO, SnO, Bi2O3 and Sb2O3 respectively.
    Type: Grant
    Filed: December 10, 2008
    Date of Patent: September 18, 2012
    Assignee: BASF SE
    Inventors: Petr Kubanek, Wolfgang Mägerlein, Ekkehard Schwab, Johann-Peter Melder, Manfred Julius
  • Microbiocides
    Patent number: 8268877
    Abstract: Compounds of formula (I) in which the substituents are as defined in claim 1, are suitable for use as microbiocides.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: September 18, 2012
    Assignee: Syngenta Crop Protection, LLC
    Inventors: Harald Walter, Daniel Stierli
  • Process for the sulfinylation of a pyrazole derivative
    Patent number: 8263783
    Abstract: The present invention relates to a process for the sulfinylation of a pyrazole derivative, characterized in that 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonitrile (II) is reacted with a sulfinylating agent selected from trifluoromethylsulfinic acid, trifluoromethylsulfinic acid anhydride, and a trifluoromethylsulfinate alkaline or alkaline earth metal salt and mixtures of the acid and/or the salt(s), in the presence of at least one amine acid complex wherein the amine(s) are selected from tertiary amines and the acid(s) are selected from hydrofluoric, hydrochloric, hydrobromic and hydroiodic acid and sulfonic acid derivatives, and with the addition of a halogenating agent.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: September 11, 2012
    Assignee: BASF SE
    Inventors: Martin Sukopp, Oliver Kuhn, Carsten Gröning, Michael Keil, Jon J. Longlet
  • Aryl-substituted heterocycles, and use thereof
    Patent number: 8263624
    Abstract: The invention relates to aryl-substituted heterocycles, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: September 11, 2012
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Michael Härter, Tobias Wunberg, Swen Allerheiligen, Marcus Bauser, Ulrich Rester, Stefan Heitmeier
  • Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
    Patent number: 8258179
    Abstract: A crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug and methods of preparing a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug, and methods of using a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug are provided.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: September 4, 2012
    Assignee: XenoPort, Inc.
    Inventors: Fenmei Yao, Mark A. Gallop, Ronald W. Barrett, Peter A. Virsik
  • Pyrazole-3-carboxamide derivative having 5-HTreceptor antagonist activity
    Patent number: 8252790
    Abstract: Disclosed is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a selective antagonist of a 5-HT2B receptor. The compound and salt are useful for treatment or prevention of various diseases and conditions associated with a 5-HT2B receptor.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: August 28, 2012
    Assignee: Raqualia Pharma Inc.
    Inventors: Tatsuya Yamagishi, Kiyoshi Kawamura, Tadashi Inoue, Yuji Shishido, Hiroaki Ito